• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Personalizing the Weight Loss Journey

Commentary
Video

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses how a personalized approach in obesity treatment can benefit access.

Another topic very popular in our coverage is personalization. Physicians have the opportunity to not only help patients quicker, but also help with access to these therapies, by figuring out which one would be the right fit initially versus trying multiple out.

I think something that we always talk about now, too, is personalization. And making sure that like, like you were saying the therapy fits the patient. So, we could save a lot of money by doing what you were saying before but what they're doing in Europe by let's start by addressing what we need to address. Let's not just start somewhere, you know, let's figure out what is the best therapy for you. We'll start there. If that doesn't work, we can start with something else. And that kind of helps with the access point too, right? Well, that's how we that's how our system typically works. Take high blood pressure, for example, a physician looks at the blood pressure cuff determines the patient has high blood pressure, and then has, you know 30 or 40 medications to be able to choose from across seven or eight different classes of medication and so the physician then looks at the medical record as the patient some additional questions and probably is able to very well pinpoint the medication or at least the class of medication that's going to best help that patient overcome their disease and have a that are disease journey, right? With them with their disease, obesity, we're so we're so new to treating obesity that we haven't thought properly about that we haven't set up our reimbursement schemes to match that we haven't set up our therapeutic teams to match that we will we always do we sometimes we just do it a little late here in the US. I think we have a lot to learn from Europe, and the answer key is in front of us, I hope we hope we make use of it.

Related Videos
Related Content